HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, A. F. Articles by Niederkorn, J. Y. Search for Related Content PubMed PubMed Citation Articles by Clark, A. F. Articles by Niederkorn, J. Y.

Inhibition of Intraocular Tumor Growth by Topical Application of the Angiostatic Steroid Anecortave Acetate

¹ From the Alcon Laboratories, Inc., Fort Worth, Texas, and ² Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, Texas.

Abstract

PURPOSE. This study examined the effect of an angiostatic agent on the growth of a highly vascularized intraocular tumor.

METHODS. A murine uveal melanoma cell line (99E1) was transplanted intracamerally into athymic nude BALB/c mice. Mice were treated topically three times per day beginning on the day of tumor transplantation and continuing through day 28. Groups included (a) 1% anecortave acetate, (b) vehicle control, or (c) no treatment. Tumor growth was scored clinically according to the volume of anterior chamber occupied by tumor. Intraocular tumor weights were determined on days 10, 14, 21, and 28. The effect of the test agents on tumor cell proliferation was examined in vitro by [³H]thymidine incorporation.

RESULTS. Tumors grew progressively in untreated mice and mice treated with the vehicle; tumors filled the entire eye by day 20 and frequently perforated the globe by day 21. By contrast, tumors treated with anecortave acetate grew significantly slower (P < 0.025) and did not perforate the eye. On days 21 and 28 the net tumor weight of the AL-3789–treated animals was 40% to 30% of controls (P < 0.05). Tumor inhibition was presumably due to the angiostatic properties of anecortave acetate because the compound did not affect tumor cell proliferation in vitro.

CONCLUSIONS. The topical ocular administration of anecortave acetate restricted the growth of a highly vascularized angiogenic intraocular tumor.

This article has been cited by other articles:

				H. Boutrid, Y. Pina, C. M. Cebulla, W. J. Feuer, T. J. Lampidis, M.-E. Jockovich, and T. G. Murray Increased Hypoxia following Vessel Targeting in a Murine Model of Retinoblastoma Invest. Ophthalmol. Vis. Sci., December 1, 2009; 50(12): 5537 - 5543. [Abstract] [Full Text] [PDF]

				Y. Pina, H. Boutrid, A. Schefler, S. Dubovy, W. Feuer, M.-E. Jockovich, and T. G. Murray Blood Vessel Maturation in Retinoblastoma Tumors: Spatial Distribution of Neovessels and Mature Vessels and Its Impact on Ocular Treatment Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1020 - 1024. [Abstract] [Full Text] [PDF]

				K. C. McKenna and J. A. Kapp Accumulation of Immunosuppressive CD11b+ Myeloid Cells Correlates with the Failure to Prevent Tumor Growth in the Anterior Chamber of the Eye J. Immunol., August 1, 2006; 177(3): 1599 - 1608. [Abstract] [Full Text] [PDF]

				M.-E. Jockovich, T. G. Murray, E. Escalona-Benz, E. Hernandez, and W. Feuer Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice. Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1264 - 1268. [Abstract] [Full Text] [PDF]

				T. M. Walker, P. R. van Ginkel, R. L. Gee, H. Ahmadi, L. Subramanian, B. R. Ksander, L. F. Meisner, D. M. Albert, and A. S. Polans Expression of Angiogenic Factors Cyr61 and Tissue Factor in Uveal Melanoma Arch Ophthalmol, December 1, 2002; 120(12): 1719 - 1725. [Abstract] [Full Text] [PDF]